Filtered By:
Specialty: Pharmaceuticals
Condition: Multiple Sclerosis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 13 results found since Jan 2013.
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Stem cell treatments drawing patients to Jackson
A Jackson, Tennessee-based doctor is offering multiple sclerosis and stroke patients a less expensive version of a cutting-edge medical treatment previously only available overseas.
Roy Schmidt, whose clinic New Life Medical Group specializes in regenerative medicine, is attracting patients from as far away as New Mexico for stem cell and hyberbaric oxygen therapy. However, the treatments aren’t covered by most insurance plans, so patients are having to pay out of pocket.
Schmidt says as recently…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 8, 2016 Category: Pharmaceuticals Authors: Michael Sheffield Source Type: news
Tau Imaging Among Breakthroughs Advancing the Fight against Alzheimer ' s
Worldwide, nearly44 million people now have Alzheimer ' s disease (AD) or related dementia, making these conditions the top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were highlighted at the Alzh...
Source: EyeForPharma - September 21, 2016 Category: Pharmaceuticals Authors: Olga Uspenskaya-Cadoz Source Type: news
Neurological diseases cost the US nearly $800 billion per year
A new paper published in the Annals of Neurology reports the most common neurological diseases pose a serious annual financial burden for the nation. The report notes that the current estimated annual cost to American society of just nine of the most common neurological diseases is staggering, totaling $789 billion in 2014 dollars. These conditions include Alzheimer's disease and other dementias, low back pain, stroke, traumatic brain injury, migraine, epilepsy, multiple sclerosis, spinal cord injury, and Parkinson's disease.
Source: World Pharma News - March 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA warns about Sanofi MS drug
The FDA is warning consumers about the risk of rare but serious cases of stroke and tears in the lining of arteries in the head and neck associated with Sanofi ’s multiple sclerosis drug, Lemtrada.
Source: PharmaManufacturing.com - November 30, 2018 Category: Pharmaceuticals Source Type: news
FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug
WEDNESDAY, Dec. 5, 2018 -- A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck, the U.S. Food and Drug...
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news
Bernie Marcus giving $80 million to Shepherd Center
Atlanta philanthropist and Home Depot co-founder Bernie Marcus and his wife are giving $80 million to Atlanta's Shepherd Center.
The grant from The Marcus Foundation, announced today, is the largest in Shepherd Center's history and will be the cornerstone of the specialty rehabilitation hospital’s most significant, transformational expansion since its founding in 1975.
Shepherd Center is a nationally-ranked hospital for patients with spinal cord injury, brain injury, stroke, multiple sclerosis,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 10, 2020 Category: Pharmaceuticals Source Type: news
NIH scientists build a cellular blueprint of multiple sclerosis lesions
Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms of the disease. Using brain tissue from humans, researchers at the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS) built a detailed cellular map of chronic MS lesions, identifying genes that play a critical role in lesion repair and revealing potential new therapeutic targets for progressive MS.
Source: World Pharma News - September 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche ’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oralBruton ’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile offenebrutinib was consistent with previous and ongoing clinical trials across more than 2,400 people to dateBasel, 17 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today p...
Source: Roche Media News - May 17, 2023 Category: Pharmaceuticals Source Type: news
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
